Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

David Taylor

Physician Assistant, Medical Morehead City, NC Physician Assistant

NPI 1114488640 CMS profile 10992464

3715 Guardian Ave, Morehead City, NC 28557

Open in the dashboard

General payments

$40,321

423 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Taylor of Morehead City, NC is reported in the CMS Open Payments database as having received $40,321 across 423 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,415 84
2024 General $8,086 86
2023 General $11,023 95
2022 General $9,619 81
2021 General $1,178 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Taylor
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to David Taylor were reported at $10,415. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year David Taylor Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,178 $156 $41–$563 $132
2022 $9,619 $185 $55–$649 $149
2023 $11,023 $199 $58–$717 $160
2024 $8,086 $206 $62–$740 $164
2025 $10,415 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $35,559 132 payments
  2. Teva Pharmaceuticals USA, Inc. $1,155 80 payments
  3. Otsuka America Pharmaceutical, Inc. $600 32 payments
  4. ITI, Inc. $590 48 payments
  5. Neurocrine Biosciences, Inc. $490 25 payments
  6. Sunovion Pharmaceuticals Inc. $478 28 payments
  7. Vanda Pharmaceuticals Inc. $282 13 payments
  8. Janssen Pharmaceuticals, Inc $228 11 payments
  9. Lundbeck LLC $220 11 payments
  10. E.R. Squibb & Sons, L.L.C. $178 12 payments
  11. Other $540 31 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $33,213 23 payments
  2. Food and Beverage $5,538 382 payments
  3. Travel and Lodging $1,009 11 payments
  4. Education $561 7 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $26,063 97 payments
  2. VRAYLAR Neuroscience $9,497 35 payments
  3. CAPLYTA $557 46 payments
  4. LATUDA $478 28 payments
  5. INGREZZA $411 20 payments
  6. REXULTI $381 19 payments
  7. Austedo XR $355 46 payments
  8. FANAPT $282 13 payments
  9. ABILIFY MAINTENA $265 14 payments
  10. HETLIOZ $250 11 payments
  11. Other $2,393 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

2,676

Median for Physician Assistant: 241

Drug cost

$654,920

Median for Physician Assistant: $4,110

Branded share of claims

25.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 20 $172,324
Invega Sustenna Paliperidone Palmitate Brand 50 $163,096
Austedo Xr Deutetrabenazine Brand 12 $92,393
Vraylar Cariprazine Hcl Brand 52 $84,640
Rexulti Brexpiprazole Brand 37 $59,476
Trintellix Vortioxetine Hydrobromide Brand 41 $24,226
Lurasidone Hcl Generic 78 $7,609
Lisdexamfetamine Dimesylate Generic 17 $5,277
Vyvanse Lisdexamfetamine Dimesylate Brand 13 $5,199
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 132 $4,642

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$17,173

Medicare's payments for the services billed

Medicare patients

73

Average age 60

Services billed

288

33 women, 40 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 55%
Depression 53%
Arthritis 37%
Diabetes 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $7,341
$7,341 52 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $175
$175 12 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $70
  • Lundbeck LLC $59
$129 37 —
INGREZZA
  • Neurocrine Biosciences, Inc. $76
$76 20 —
CAPLYTA
  • ITI, Inc. $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

423 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record